Sanofi/Regeneron on notice as FDA reviews GSK’s Nucala for nasal polypsSanofi and Regeneron’s Dupixent has had the US market for the treatment of chronic rhinosinusitis with nasal polyps Share XSanofi/Regeneron on notice as FDA reviews GSK’s Nucala for nasal polypshttps://pharmaphorum.com/news/dupixent-on-notice-as-fda-reviews-gsks-nucala-for-nasal-polyps/
AZ’s Fasenra on target in nasal polyps trialAstraZeneca’s Fasenra (benralizumab) injected drug cuts the size of nasal polyps and nasal blockage in patients with chronic Share XAZ’s Fasenra on target in nasal polyps trialhttps://pharmaphorum.com/news/azs-fasenra-on-target-in-nasal-polyps-trial/
GSK eyes nasal polyps use for Nucala after trial successGlaxoSmithKline is eyeing another indication for its Nucala (mepolizumab) biologic drug after a phase 3 trial in inflammation Share XGSK eyes nasal polyps use for Nucala after trial successhttps://pharmaphorum.com/news/gsk-eyes-nasal-polyps-use-for-nucala-after-trial-success/
Regeneron/Sanofi get EU okay for Dupixent in “asthma of the sinuses”Regeneron and Sanofi’s immunology drug Dupixent has been approved for a third indication in Europe, adding the treatment Share XRegeneron/Sanofi get EU okay for Dupixent in “asthma of the sinuses”https://pharmaphorum.com/news/regeneron-sanofi-get-eu-okay-for-dupixent-in-asthma-of-the-sinuses/
Sanofi/Regeneron’s Dupixent could be first biologic approved for nasal polypsTrials of Sanofi and Regeneron’s drug Dupixent (dupilumab) have shown positive results for treating patients suffering from chronic Share XSanofi/Regeneron’s Dupixent could be first biologic approved for nasal polypshttps://pharmaphorum.com/news/sanofi-regenerons-dupixent-could-be-first-biologic-approved-for-nasal-polyps/
